Technical Evaluation Of JewelPUMP In Type 1 Diabetic Patients Treated With Extern Insulin Pump

NCT ID: NCT01640210

Last Updated: 2012-07-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2012-03-31

Brief Summary

The main objective of the study is to verify the reliability of the solutes volumes issued by the Debiotech JewelPUMPTM controlled by its remote.

Three clinical sites are participating in this study:

• CHSF, Service of Endocrinology and Diabetology, CORBEIL-ESSONNES (91): Dr. Guillaume CHARPENTIER, Dr. Sylvia FRANC
• Grenoble University Hospital, Department of Endocrinology, Diabetes Diseases, Nutrition, GRENOBLE (38): Pr Pierre-Yves BENHAMOU
• CHU Jean Minjoz, Department of Endocrinology and Diabetology, BESANCON (25): Professor Alfred PENFORNIS, Dr. Annie CLERGEOT

The study will be conducted in 20 patients with type 1 diabetes treated by external insulin pump. Patients will be informed of the study during a screening visit. After signing the informed consent, they will return to the center where they will wear a JewelPUMPTM containing saline water, they will use their pumps in parallel. The investigator or nurse education will form the operation of the JewelPUMPTM and they will be instructed to replicate the same settings between their usual and JewelPUMPTM pump. The patient will be asked to complete visual analog scales of satisfaction with their usual treatment and the various elements of the devices (usual pump, and JewelPUMPTM) have been weighed using a precision balance to have a form of a base for comparison.

Patients will leave home for a period of about three days, but they will have to come back every days to the center. They will be asked to collect all events arising (programming problems to deliver a bolus, hardware failure ...) in a booklet.

At the end of study visit, patients will return to the center where the volumes will be assessed by the perfused weighed the various components and devices where they will complete the visual analog scales of satisfaction at endpoint.

Conditions

Type1diabetes

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

JewelPUMP (insulin patch pump)

The study will be proposed during the visit of selection.

Visit of inclusion:

This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.

Patients treated with insulin pump will be instructed to reproduce the same "programming" between their usual pump and the JewelPUMP, they will use in parallel.

Volume infused will be evaluated during a period of basal and bolus with a precision scale.

Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:

Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.

Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Type 1 Diabetic patient treated by external insulin pump for at least 6 months
• Patient with a HbA1c < 9%
• Patient age over 18 years of age
• Patient having signed the consent and informed form
• Patient affiliated with the social security

Exclusion Criteria

• Patients with diabetes type 2
• Patient pregnant or likely to be
• All serious pathologies that can interfere with the study
• Incompatible psychiatric pathologies with the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Guillaume Charpentier, MD

Role: PRINCIPAL_INVESTIGATOR

CHSF

Locations

CHU Jean Minjoz

Besançon, , France

University Hospital Grenoble

Grenoble, , France

Countries

France

Other Identifiers

2011-A00666-35

Identifier Type: -

Identifier Source: org_study_id